Data from Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

Autor: Carla M.L. van Herpen, I. Jolanda M. de Vries, Cornelis J.A. Punt, Kris C.P. Vissers, Peter F.A. Mulders, Steven Teerenstra, Ruurd Torensma, Ingrid M.E. Desar, Joep M.D. Galama, Michel A.M. Olde Nordkamp, Joannes F.M. Jacobs, Sasja F. Mulder

Purpose: The tyrosine kinase inhibitors sorafenib and sunitinib have efficacy in several types of cancer. Recent studies indicate that these agents affect the immune system. The way it affects the immune response to influenza vaccination is unknown.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78ea26265ce0eb60fc0bafe796f69558
https://doi.org/10.1158/1078-0432.c.6519432

Data from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Autor: I. Jolanda M. de Vries, Carl G. Figdor, Cornelis J.A. Punt, Winald R. Gerritsen, Christian U. Blank, Sander Kelderman, Joannes F.M. Jacobs, Rutger H.T. Koornstra, Sandra A.J. Croockewit, Roel D.M. Mus, Marieke E.B. Welzen, Michelle M. van Rossum, Willeke A.M. Blokx, Katja Petry, Gregor Winkels, Jurjen Tel, Tom G.M. van Oorschot, Michel A.M. Olde Nordkamp, Jeanette M. Pots, Annemiek J. de Boer, Nicole M. Scharenborg, Mandy W.M.M. van de Rakt, Tjitske Duiveman-de Boer, Erik H.J.G. Aarntzen, Florian Wimmers, Harm Westdorp, Kalijn F. Bol, Gerty Schreibelt

Purpose: Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro–generated monocyte-derived DCs, which require extensive in vitro manipulation. Here, we report on a clinical study exploiting primary CD1c+ myeloid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::492a00959142946a6e6448b4074be089
https://doi.org/10.1158/1078-0432.c.6523763.v1

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Autor: Mandy W.M.M. van de Rakt, Kalijn F. Bol, Roel Mus, Gerty Schreibelt, Otto C. Boerman, I. Jolanda M. de Vries, Cornelis J. A. Punt, Michelle M. van Rossum, Wim J.G. Oyen, Sandra Croockewit, Jeanette M. Pots, Erik H.J.G. Aarntzen, Tom G. M. van Oorschot, Chantal A. A. van der Graaf, Michel A.M. Olde Nordkamp, Annemiek J. de Boer, Carl G. Figdor, Gosse J. Adema, Willeke A. M. Blokx, Nicole M. Scharenborg

Publikováno v: Cancer Immunology, Immunotherapy
Cancer Immunology Immunotherapy, 65, 327-39
Cancer Immunology Immunotherapy, 65, 3, pp. 327-39
Cancer immunology, immunotherapy, 65(3), 327-339. Springer Science and Business Media Deutschland GmbH

Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer patients, predominantly with DC matured with pro-inflammatory cytokines and prostaglandin E2. We studied the safety and efficacy of vaccination with monocyte-derived DC matured w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21ba2279ffaeb52be80bcb4f0a01ce39
https://hdl.handle.net/2066/171284

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Autor: Carl G. Figdor, Harm Westdorp, Sander Kelderman, Winald R. Gerritsen, Katja Petry, Christian U. Blank, Marieke E. B. Welzen, Willeke A. M. Blokx, Nicole M. Scharenborg, Michel A.M. Olde Nordkamp, Jurjen Tel, Gregor Winkels, Mandy W.M.M. van de Rakt, Kalijn F. Bol, I. Jolanda M. de Vries, Jeanette M. Pots, Erik H.J.G. Aarntzen, Rutger H. T. Koornstra, Sandra Croockewit, Gerty Schreibelt, Florian Wimmers, Annemiek J. de Boer, Roel Mus, Cornelis J. A. Punt, Joannes F M Jacobs, Michelle M. van Rossum, Tjitske Duiveman-de Boer, Tom G. M. van Oorschot

Publikováno v: Clinical cancer research, 22(9), 2155-2166. American Association for Cancer Research Inc.
Clinical Cancer Research, 22, 9, pp. 2155-2166
Clinical Cancer Research, 22, 2155-2166

Purpose: Thus far, dendritic cell (DC)-based immunotherapy of cancer was primarily based on in vitro–generated monocyte-derived DCs, which require extensive in vitro manipulation. Here, we report on a clinical study exploiting primary CD1c+ myeloid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e085285c0ad42e906fde164cace2ff
https://pubmed.ncbi.nlm.nih.gov/26712687

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

Autor: I. Jolanda M. de Vries, Marieke E. B. Welzen, Annemiek J. de Boer, Carl G. Figdor, Mandy W.M.M. van de Rakt, Willeke A. M. Blokx, Nicole M. Scharenborg, Gerty Schreibelt, Gerold Schuler, Michel A.M. Olde Nordkamp, Kalijn F. Bol, Jonathan M. Austyn, Cornelis J. A. Punt, Sandra Croockewit, Jeanette M. Pots, Joannes F M Jacobs, Erik H.J.G. Aarntzen, Bart Neyns, Tom G. M. van Oorschot, Michelle M. van Rossum, Roel Mus

Publikováno v: Oncoimmunology
Oncoimmunology, 4, 8, pp. e1019197
Oncoimmunology, 4, e1019197
Oncoimmunology, 4(8). Landes Bioscience

Contains fulltext : 153217.pdf (Publisher’s version ) (Open Access) Autologous dendritic cell (DC) therapy is an experimental cellular immunotherapy that is safe and immunogenic in patients with advanced melanoma. In an attempt to further improve t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e116a5955dbb7bc389e41dba2e0bb80d
https://hdl.handle.net/2066/153217